Market openNon-fractional

Immunome/IMNM

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Immunome

Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.

Ticker

IMNM

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Bothell, United States

Employees

62

Immunome Metrics

BasicAdvanced
$727M
Market cap
-
P/E ratio
-$7.82
EPS
1.88
Beta
-
Dividend rate
$727M
1.88
10.184
10.066
0.422
0.569
-15.16%
-154.98%
28.366
2.53
2.53
-7.855
436.51%
214.84%
33.30%

What the Analysts think about Immunome

Analyst Ratings

Majority rating from 6 analysts.
Buy

Immunome Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-12,940.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$1M
-73.68%
Net income
-$129M
39.74%
Profit margin
-12,940.00%
431.02%

Immunome Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 261.78%
QuarterlyAnnual
Q1 23
Q2 23
Q4 23
Q1 24
Q2 24
Actual
-$0.35
-$0.46
-$4.22
-$2.51
-
Expected
$0.59
-$0.16
-$0.28
-$0.69
-$0.39
Surprise
-159.83%
187.50%
1,389.41%
261.78%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market openNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Immunome stock?

Immunome (IMNM) has a market cap of $727M as of July 05, 2024.

What is the P/E ratio for Immunome stock?

The price to earnings (P/E) ratio for Immunome (IMNM) stock is 0 as of July 05, 2024.

Does Immunome stock pay dividends?

No, Immunome (IMNM) stock does not pay dividends to its shareholders as of July 05, 2024.

When is the next Immunome dividend payment date?

Immunome (IMNM) stock does not pay dividends to its shareholders.

What is the beta indicator for Immunome?

Immunome (IMNM) has a beta rating of 1.88. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Immunome stock

Buy or sell Immunome stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing